Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

METEOR trial: cabozantinib vs everolimus in advanced renal cell carcinoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.06.16
Views: 1558
Rating:

Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA

Dr Choueiri speaks with ecancertv at ASCO 2016 about results from METEOR, a randomised phase III trial of cabozantinib for patients with advanced renal cell carcinoma (RCC), compared to everolimus.

Cabozantinib displayed a significant impact on previously treated patients, improving median overall survival from 16.5 months in the everolimus arm to 21.4 months for cabozantinib, and a 33% reduction in the rate of death

He also highlights the scale of the trial, from the international team gathering data to the impact on standard of care in RCC. 

ecancer's filming at ASCO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

BGICC conference


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation